5,7-diisopropylisoquinoline | 1443013-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 5,7-diisopropylisoquinoline
• 英文别名: 5,7-di(propan-2-yl)isoquinoline
• CAS: 1443013-11-3
• 化学式: C₁₅H₁₉N
• 分子量: 213.323
• InChiKey: XDWVHXPKUTTXDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5,7-diisopropylisoquinoline 在 布纳唑嗪 作用下， 以 四氢呋喃 为溶剂， 生成 1-(3,5-dimethylphenyl)-5,7-diisopropylisoquinoline
  参考文献：
  名称：

  Novel Organic Light Emitting Materials

  摘要：

  提供含有2-苯基异喹啉配体的新型磷光金属配合物，异喹啉环上至少有两个取代基。所披露的化合物具有低的升华温度，使得易于提纯并制造成为各种OLED设备。

  公开号：

  US20130146848A1

文献信息

• INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS
  申请人：Aronov Alex

  公开号：US20090048250A1

  公开（公告）日：2009-02-19

  The present invention provides compounds of formula I: These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.

  本发明提供了I式化合物：这些化合物及其药学上可接受的组合物通常用作激酶抑制剂，特别是作为PRAK、GSK3、ERK2、CDK2、MK2、SRC、SYK和AuroRA-2的抑制剂。因此，本发明的化合物和组合物可用于治疗或减轻各种疾病的严重程度，包括但不限于心脏疾病、糖尿病、阿尔茨海默病、免疫缺陷病、炎症性疾病、过敏性疾病、自身免疫性疾病、破坏性骨疾病（如骨质疏松症）、增生性疾病、传染病和病毒性疾病。
• Novel organic light emitting materials
  申请人：Universal Display Corporation

  公开号：EP2602302A2

  公开（公告）日：2013-06-12

  Novel phosphorescent metal complexes containing 2-plienylisoquinoline ligands with at least two substituents on the isoquinoline ring are provided. The disclosed compounds have low sublimation temperatures that allow for ease of purification and fabrication into a variety of OLED devices.

  本发明提供了含有 2-芘基异喹啉配体的新型磷光金属复合物，其异喹啉环上至少有两个取代基。所公开的化合物具有较低的升华温度，易于纯化和制造成各种有机发光二极管设备。
• Organic electroluminescent materials and devices
  申请人：Universal Display Corporation

  公开号：US10454046B2

  公开（公告）日：2019-10-22

  Novel phosphorescent metal complexes containing 2-phenylisoquinoline ligands with at least two substituents on the isoquinoline ring are provided. The disclosed compounds have low sublimation temperatures that allow for ease of purification and fabrication into a variety of OLED devices.

  本研究提供了含有 2-苯基异喹啉配体的新型磷光金属复合物，其异喹啉环上至少有两个取代基。 所公开的化合物具有较低的升华温度，易于纯化和制造成各种有机发光二极管设备。
• NOVEL ORGANIC LIGHT EMITTING MATERIALS
  申请人：Universal Display Corporation

  公开号：EP2602302B1

  公开（公告）日：2016-06-29
• Aryl-Quinolyl Compounds and Their Use
  申请人：Niculescu-Duvaz Ion

  公开号：US20110053946A1

  公开（公告）日：2011-03-03

  The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain aryl-quinolyl compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.